CMSC 2016 Annual Meeting – women with multiple sclerosis have significant depression, fatigue, decline in cognitive function

CMSC 2016 Annual Meeting – women with multiple sclerosis have significant depression, fatigue, decline in cognitive function

Researchers at the University of Arizona studied the psychosocial symptoms felt by a group of female patients with multiple sclerosis (MS) from the southwestern United States, and found significant relationships between depression, fatigue, and cognitive decline — symptoms also related with poorer quality of life and reduced mental and physical health.

The findings suggested that education of healthcare providers about these symptoms may improve MS care, and patients may benefit from self-help intervention programs.

The abstract, titled “Depression, Fatigue, Declines in Cognitive Function, and Uncertainty and Quality of Life Outcomes in Women with Multiple Sclerosis,” was recently presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), as part of a session named Psychosocial: Cognition, Depression.

The study included data from more than 200 female MS patients, and the main objectives were the assessment of a possible relationship between depression, fatigue and cognitive decline, and how these symptoms and other factors, such as uncertainty and self-management, influence the quality of life of this particular patient population.

According to the findings, researchers observed significant correlations between depression and fatigue, depression and cognitive function decline, and fatigue and declines in cognitive function. These three symptoms were all found to be significantly related to uncertainty and associated with reduced physical and mental health. Also, depression, fatigue, and decline in cognitive function were found to be significantly associated with a poorer quality of life in female patients.

Researchers stated that such findings point to the existence of a symptom cluster in MS of depression, fatigue, and cognitive function decline and recommended establishing an intervention aimed at educating health providers for the three symptoms.

The research team also suggested that MS patients might benefit from the development of a self-help program. “A research study including a larger population of women with MS located throughout the United States, and not just the southwest, is necessary before any education aimed at health-care professionals or individuals with MS is developed or implemented,” the researchers concluded.

MS is an autoimmune disease characterized by chronic damage in the central nervous system. It is the most prevalent neurologic disease among young and middle-aged adults and, although it does not always negatively affect life expectancy, it is associated with healthcare costs of $10 billion annually.

By Margarida Azevedo

Multiple Sclerosis News Today

Elizabeth Porco

Comments are closed.

  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM